Last reviewed · How we verify

NCT05990608

Peabody Developmental Motor Scaling In Children With Period Duchenne Muscular Dystrophy

Completed Last updated 14 August 2023
What this trial tests

trial testing Peabody Developmental Motor Scales-2, PDMS in Duchenne Muscular Dystrophy (DMD) in 48 participants. Completed in 30 July 2023.

Timeline
30 July 2021
Primary endpoint
30 July 2022
30 July 2023

Quick facts

Lead sponsorOndokuz Mayıs University
StatusCompleted
Study typeOBSERVATIONAL
Enrollment48
Start date30 July 2021
Primary completion30 July 2022
Estimated completion30 July 2023
Sites1 location across Turkey (Türkiye)

Drugs / interventions tested

Conditions studied

Sponsor

Ondokuz Mayıs University

Who can join

Adults 3 to 5, any sex, with Duchenne Muscular Dystrophy (DMD). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To perform the reliability and validity study of the Peabody Developmental Motor Scale (Peabody Developmental Motor Scales-2) in children with Duchenne Muscular Dystrophy (DMD).

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Duchenne Muscular Dystrophy (DMD)

Currently open trials in the same condition.

Other Ondokuz Mayıs University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05990608.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing